MedPath

Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer

Not Applicable
Recruiting
Conditions
Lung Non-Small Cell Carcinoma
Stage I Lung Cancer AJCC v8
Stage IA2 Lung Cancer AJCC v8
Stage IB Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8
Stage IIA Lung Cancer AJCC v8
Stage IA1 Lung Cancer AJCC v8
Stage IA3 Lung Cancer AJCC v8
Stage IIB Lung Cancer AJCC v8
Interventions
Other: Informational Intervention
Other: Best Practice
Other: Questionnaire Administration
Registration Number
NCT05292521
Lead Sponsor
Roswell Park Cancer Institute
Brief Summary

This clinical trial studies the effect of a quality of life intervention on decision-making in patients with early-stage lung cancer who are undergoing standard of care surgery or stereotactic body radiation therapy (SBRT). Providing quality of life outcome data to patients deciding between surgery and SBRT may help decrease decision regret and increase patient satisfaction with their care.

Detailed Description

PRIMARY OBJECTIVE:

I. Determine the effect of provision of quality-of-life (QOL) information versus usual care for standard of care surgery or SBRT treatment on decision regret.

SECONDARY OBJECTIVES:

I. Determine the effect of provision of QOL information versus usual care for standard of care surgery or SBRT treatment on QOL measures.

II. Determine the influence of socioeconomic status on the relationship between decision regret and QOL information associated with each treatment modality.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP A: Patients receive study QOL intervention fact sheet during the initial consult that occurs 4 weeks prior to the standard of care surgery or SBRT. Patients have an opportunity to review the QOL fact sheet in person and discuss any questions with the treating physician(s).

GROUP B: Patients receive usual care during the initial consult that occurs 4 weeks prior to the standard of care surgery or SBRT.

Patients are followed up at 1, 3, and 6 months after standard of care surgery or SBRT.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Age >= 18 years
  • Radiographic stage I-II non-small cell lung cancer (NSCLC)
  • Eligible for both surgery and SBRT
  • Able to provide informed consent in English
  • Have verbal fluency in English
  • Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Exclusion Criteria
  • Radiographic stage III-IV NSCLC
  • Eligible for either only surgery or SBRT, but not both
  • Eligible for palliative-intent treatments or supportive care only.
  • Pregnant female participants.
  • Unwilling or unable to follow protocol requirements
  • Any condition which in the investigator's opinion deems the participant an unsuitable candidate
  • Cognitively impaired adults/adults with impaired decision-making capacity
  • Individuals who are not yet adults (infants, children, teenagers)
  • Prisoners

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group B (usual care)Questionnaire AdministrationPatients receive usual care during the initial consult that occurs 4 weeks prior to the standard of care surgery or SBRT.
Group A (QOL fact sheet)Informational InterventionPatients receive study QOL intervention fact sheet during the initial consult that occurs 4 weeks prior to the standard of care surgery or SBRT. Patients have an opportunity to review the QOL fact sheet in person and discuss any questions with the treating physician(s).
Group B (usual care)Best PracticePatients receive usual care during the initial consult that occurs 4 weeks prior to the standard of care surgery or SBRT.
Group A (QOL fact sheet)Questionnaire AdministrationPatients receive study QOL intervention fact sheet during the initial consult that occurs 4 weeks prior to the standard of care surgery or SBRT. Patients have an opportunity to review the QOL fact sheet in person and discuss any questions with the treating physician(s).
Primary Outcome Measures
NameTimeMethod
Decision regretAt 6 months

Compare the extent of decision regret based on Decision Regret Scale between the provision of quality of life (QOL) information versus usual care for standard of care surgery or stereotactic body radiation therapy (SBRT) treatment. The five-point decision regret score will be converted to a 100-point score as described by others, where a higher score reflects an increased decision regret. In this schema, a decision regret score \> 25 % is deemed moderate to severe regret. The dichotomized decision regret will be modeled as a function of group, time, and their interaction using a generalized estimating equations (GEE) logistic regression model with an autoregressive covariance structure. The rates of less than moderate to severe regret will be compared between groups at 6-months using a one-sided test about the appropriate contrast of model estimates.

Secondary Outcome Measures
NameTimeMethod
Quality of Life (EORTC QLQ-C30)Up to 6 months

Will compare QOL measures based on the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) between the provision of QOL information versus usual care for standard of care surgery or SBRT treatment.

Quality of Life (QOL)Up to 6 months

Will compare QOL measures based on the lung cancer- specific questionnaire (EORTC QLQ-LC13) between the provision of QOL information versus usual care for standard of care surgery or SBRT treatment.

Difference in consideration of regretUp to 6 months

Compare decisions about treatment for early stage lung cancer and examined whether regret is a consideration in treatment decisions between those who received the quality of life fact sheet and those who did not.

Trial Locations

Locations (1)

Roswell Park Cancer Institute

🇺🇸

Buffalo, New York, United States

© Copyright 2025. All Rights Reserved by MedPath